Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is described in its public communications as a company that owns rights to pharmaceutical royalties and operates as a pharmaceutical royalty company. Its recurring news releases focus on financial results and business updates related to this royalty-based model. Each quarter, the company issues press releases detailing net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses from continuing operations.
These earnings announcements highlight how changes in sales of licensed products by TherapeuticsMD’s licensees affect license revenue, and how the company’s transition from a commercializing pharmaceutical business to a royalty-based business has influenced its cost structure. The company frequently discusses reductions in operating expenses, including lower general and administrative costs, and refers to efficiencies realized as a royalty-based business with more limited infrastructure.
Another recurring theme in TherapeuticsMD’s news is its evaluation of strategic alternatives. In multiple press releases, the company states that it is exploring a variety of potential transactions, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the company. It also notes that there can be no assurance of any particular outcome and that no timetable has been set for this process.
Visitors to the TXMD news page can review this sequence of financial updates, commentary on the company’s royalty assets, and disclosures about its strategic review process. For investors and followers of TXMD stock, these news items provide insight into the company’s royalty revenue trends, expense profile, and the status of its exploration of possible strategic alternatives over time.
TherapeuticsMD has agreed to divest its vitaCare Prescription Services business to GoodRx for $150 million in cash, plus up to $7 million contingent on vitaCare's 2023 performance. The deal is set to close in Q2 2022, allowing TXMD to focus on its core women's health business. CEO Hugh O’Dowd expressed confidence in GoodRx's ability to enhance patient access. TXMD will discuss this transaction in its earnings call on March 10, 2022.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will report its Q4 2021 financial results on March 10, 2022, before the U.S. markets open. Executive management will hold a conference call and webcast at 8:30 a.m. ET to discuss the results.
Interested parties can access the conference via a toll-free number or through a webcast link provided. A replay will be available for 30 days on the company's website.
Galderma, the largest independent dermatology company, announced the appointment of Karen L. Ling to its Advisory Committee, effective March 1, 2022. Ms. Ling brings over 25 years of global human resources experience from executive positions at AIG, Allergan, Merck, and Wyeth, focusing on talent management and organizational culture. Currently, she serves on the Boards of iRhythm Technologies (NASDAQ: IRTC) and TherapeuticsMD (NASDAQ: TXMD). Both Thomas Ebeling and Flemming Ørnskov expressed enthusiasm about her joining, highlighting her strengths in human capital management and diversity initiatives.
TherapeuticsMD, Inc. (NASDAQ:TXMD) announced that the FDA denied proposed revisions to the manufacturing testing limits for ANNOVERA through a Supplemental New Drug Application (sNDA). The FDA provided recommendations for further information to support future revisions. As a result, the company will continue to supply ANNOVERA under the existing manufacturing specifications approved in its original NDA. ANNOVERA is recognized as a long-lasting, reversible birth control option approved by the FDA in August 2018.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has settled its U.S. patent litigation concerning BIJUVA® with Amneal Pharmaceuticals. The settlement allows Amneal to commercially launch its generic version of BIJUVA by May 25, 2032, or sooner under specific conditions. The litigation had been ongoing since 2020 and stemmed from Amneal's attempt to market a generic variant before the patent expiration date of November 21, 2032. CEO Rob Finizio emphasizes the strength of the patent estate for BIJUVA, despite the early settlement.
TherapeuticsMD, Inc. (TXMD) reported Q3 2021 financial results, showing a total net product revenue of $24.5 million, up 41.1% from Q3 2020. ANNOVERA prescriptions rose by 62.7%, totaling 8,351 prescriptions. The company plans a $40 million cost reduction initiative for 2022, with an additional $20 million expected from divesting vitaCare. Hugh O'Dowd is appointed CEO. Despite revenue growth, the net loss increased to $47.4 million. Manufacturing issues related to ANNOVERA could impact future revenue covenants.
TherapeuticsMD has announced significant leadership changes, appointing Hugh O’Dowd as the new Chief Executive Officer, effective on or before December 31, 2021. He succeeds Robert G. Finizio, who will transition to Vice Chair of the Board. O’Dowd, previously President and CEO of Neon Therapeutics, has a strong track record in the pharmaceutical industry. Finizio expressed confidence in O’Dowd's capabilities to advance the company’s growth and mission in women’s healthcare, addressing unique challenges throughout various life stages.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will announce its third quarter 2021 financial results on November 11, 2021, before U.S. markets open. A conference call is scheduled for 8:30 a.m. ET on the same day, providing insights into the results and business updates. Investors can access the call by dialing 866-665-9531 (US) or 724-987-6977 (international) with Conference ID 6341637. A live webcast will also be available on the company's website, with a replay accessible for 30 days.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has appointed Mark Glickman as its new Chief Business Officer. Glickman, who has extensive experience in commercial roles at various pharmaceutical companies, will receive 660,000 restricted stock units (RSUs) and 260,000 performance stock units (PSUs) as part of his inducement package. The RSUs will vest over three years, while the PSUs are tied to revenue performance metrics. The appointment is part of the company's strategy to strengthen its leadership in women's healthcare.
Theramex has launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) in Europe and the UK. This body-identical hormone therapy is the first of its kind for post-menopausal women with intact uterus, aimed at alleviating symptoms of estrogen deficiency. Unlike synthetic hormones, Bijuva® and Bijuve® are chemically identical to natural hormones, associated with lower health risks. Clinical trials show significant improvements in vasomotor symptoms and quality of life during treatment, making it a vital option for women seeking effective HRT.